NDA 206756 · Boehringer Ingelheim
Stiolto Respimat
Olodaterol Hydrochloride, Tiotropium Bromide · Inhalation
Last checked: Nov 19, 2026Latest source record: Dec 30, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
May 21, 2015
Approved uses
3
Original approval plus efficacy supplements
Registered trials
79
28 Phase 3, 0 recruiting
FAERS reports
5,135
1,966 serious, 373 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 30, 2025.
STIOLTO RESPIMAT is a combination of tiotropium bromide, an anticholinergic and olodaterol, a long-acting beta 2 -adrenergic agonist (LABA) indicated for the long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1.1 ) Important limitations: STIOLTO RESPIMAT is NOT indicated to treat acute deterioration of COPD. ( 1.1 ) STIOLTO RESPIMAT is NOT indicated to treat asthma. ( 1.1 ) 1.1 Maintenance Treatment of COPD STIOLTO RESPIMAT is a combination of tiotropium bromide and olodaterol indicated for long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Important Limitations of Use STIOLTO RESPIMAT is not indicated to treat acute deteriorations of COPD [see Warnings and Precautions (5.2) ]. STIOLTO RESPIMAT is not indicated to treat asthma. The safety and effectiveness of STIOLTO RESPIMAT in asthma have not been established.
Mechanism: STIOLTO RESPIMAT STIOLTO RESPIMAT contains both tiotropium and olodaterol. The properties described below for the individual components apply to STIOLTO RESPIMAT. These drugs represent 2 different classes of medication (an anticholinergic and a beta-agonist) that have different effects on clinical and physiological indices. Tiotropium Tiotropium is a long-acting, muscarinic antagonist which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors, M 1 to M 5 . In the airways, it exhibits pharmacological effects through inhibition of M 3...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 5, 2018 Supplement 9 · Efficacy LabelLetter
- Mar 18, 2016 Supplement 2 · Efficacy LabelLetter
- May 21, 2015 Original approval · Type 4 - New Combination ReviewLabelLetter
1 products under this application
- STIOLTO RESPIMAT · OLODATEROL HYDROCHLORIDE EQ 0.0025MG BASE/INH; TIOTROPIUM BROMIDE EQ 0.0025MG BASE/INH · SPRAY, METERED, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Olodaterol" as an intervention, any sponsor and status, largest first.
Boehringer IngelheimBoehringer Ingelheim
NCT02296138 · 7,903 participants · Start Jan 13, 2015 · Primary completion Mar 8, 2017
Drug: olodaterol; tiotropium and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Andalusia, Alabama; Birmingham, Alabama; Florence, Alabama · 818 sites in all
- Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT01431274 · 2,624 participants · Start Sep 2011 · Primary completion Sep 2013
Drug: tiotropium + olodaterol; tiotropium and 3 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Jasper, Alabama; Mobile, Alabama; Boulder, Colorado · 239 sites in all
- Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT01431287 · 2,539 participants · Start Sep 2011 · Primary completion Nov 2013
Drug: tiotropium + olodaterol; tiotropium + olodaterol and 3 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Greer, California; Fort Collins, Colorado; Danbury, Connecticut · 240 sites in all
- Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT01696058 · 1,137 participants · Start Sep 2012 · Primary completion Oct 2013
Drug: Tiotropium; Placebo matching Olodaterol and 2 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Anniston, Alabama; Birmingham, Alabama; Mobile, Alabama · 94 sites in all
- Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT01694771 · 1,134 participants · Start Sep 2012 · Primary completion Aug 2013
Drug: Tiotropium; Placebo matching Olodaterol and 2 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Florence, Alabama; Jasper, Alabama; Phoenix, Arizona · 90 sites in all
- Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease IIPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00796653 · 937 participants · Start Jan 2009 · Primary completion Dec 2010
Drug: Olodaterol (BI 1744); Olodaterol (BI 1744) and 2 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Capital Federal, Argentina; Mar del Plata, Argentina; Mendoza, Argentina · 98 sites in all
- Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease IPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00793624 · 906 participants · Start Feb 2009 · Primary completion Dec 2010
Drug: Olodaterol (BI 1744); Olodaterol (BI 1744) and 3 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Capital Federal, Argentina; Mar del Plata, Argentina; Monte Grande, Argentina · 93 sites in all
- Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary DiseasePivotal-lookingTerminated
Università degli Studi di FerraraAcademic, hospital or other
NCT03662711 · 843 participants · Start Nov 11, 2018 · Primary completion Oct 26, 2022
Drug: Bronchodilator Agents; Bronchodilator Agents and 16 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Cassano delle Murge, Italy; Bari, Italy; Telese Terme, Italy · 39 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea934
- cough422
- drug ineffective345
- off label use304
- fatigue254
- headache245
- death230
- diarrhoea219
- pneumonia218
- chronic obstructive pulmonary disease207
- nausea193
- dizziness192
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2015 | 185 |
| 2016 | 423 |
| 2017 | 539 |
| 2018 | 479 |
| 2019 | 428 |
| 2020 | 480 |
| 2021 | 434 |
| 2022 | 424 |
| 2023 | 408 |
| 2024 | 444 |
| 2025 | 473 |
| 2026 | 417 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Stiolto Respimat (Tiotropium Br/Olodaterol HCl)
2024 spending
$449M
Beneficiaries
167,334
695,441 claims
Per beneficiary
$2,681
$113.32 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $264,984,003 |
| 2021 | $345,628,078 |
| 2022 | $387,118,055 |
| 2023 | $432,253,137 |
| 2024 | $448,588,557 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study.
Ichinose M, Nishimura M, Akimoto M, et al. · Int J Chron Obstruct Pulmon Dis 2018 · Clinical Trial, Phase III, Multicenter Study
- Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO® studies.
Ferguson GT, Maltais F, Karpel J, et al. · NPJ Prim Care Respir Med 2020 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis.
Miravitlles M, Urrutia G, Mathioudakis AG, et al. · Respir Res 2017 · Meta-Analysis, Systematic Review
- β-Blockers in COPD: A Cohort Study From the TONADO Research Program.
Maltais F, Buhl R, Koch A, et al. · Chest 2018 · Clinical Trial, Phase III, Multicenter Study
- Effect of fixed-dose tiotropium/olodaterol combined therapy on exercise-related outcome measures in individuals with chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Alsubheen SA, Rodrigues M, Thorlund K · Expert Rev Respir Med 2025 · Systematic Review, Meta-Analysis
- Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD.
Maltais F, Aumann JL, Kirsten AM, et al. · Eur Respir J 2019 · Clinical Trial, Phase IV, Comparative Study
Sponsor: Boehringer Ingelheim
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.